ClinicalTrials.gg
RecruitingNCT05100056BV-MAZOVIAUpdated May 27, 2026

A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma

An observational study in Hodgkin Lymphoma, sponsored by Takeda. Recruiting at 13 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Takeda · Observational

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
70
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 15 studies in Hodgkin Disease by Takeda — 3 open to participants now, 4 under way, none of them phase 3. Hodgkin Disease · Takeda.

Started
2022
with 1 other
Observational
6 of 15
2 open now
Registered
12th of 15
by date

Among the 15 studies in Hodgkin Disease by Takeda, this one is one of 2 that started in 2022, is one of 6 observational ones, and was the 12th registered.

Hodgkin Disease

1,384 studies on the registry are indexed under Hodgkin Disease; 161 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

3 of the 15 studies in Hodgkin Disease by Takeda are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 134 Hodgkin Disease studies recruiting now, 71 (53%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hodgkin Disease by Takeda, or all of them as a file.
02

Study summary

The main aim is to check how effective BV is for treating adults with HL.

Study medication will be prescribed according to the clinic's standard practice.

Participants will visit the study clinic 5 times, once every 12 weeks. When study treatment has completed, a follow-up visit will be scheduled every 3 months during the first year and every 4-6 months during the next year.

Read the detailed description

This is a prospective, observational study in participants with HL who underwent or are candidates for ASCT and receiving or will receive the standard treatment of BV. This study will assess the safety profile and effectiveness of BV in pre and post-ASCT in the real-world clinical practice.

The study will enroll approximately 70 participants.

The data will be collected and recorded in electronic case report forms (e-CRFs) in scope of National Drug Program (NDP). All the participants will be assigned to two observational cohorts:

  • HL Participants: BV Salvage Pre-ASCT
  • HL Participants: BV Consolidation Treatment Post-ASCT

This multi-center trial will be conducted in Poland. All participants will be followed up for 24 months. The overall duration of the study will be approximately 4.5 years.

03

Conditions studied

  • Hodgkin Lymphoma

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants diagnosed with HL (previously enrolled in BV HL NDP) who underwent or are candidates for ASCT will be enrolled in this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Adult participant (aged greater than or equal to [>=18] years) that underwent or are candidates for and were enrolled in BV HL NDP receiving treatment according to the Summary of Product Characteristics for Adcetris and NDP.

Exclusion criteria

Exclusion Criteria:

  1. Currently participates or plans to participate in any interventional clinical trial.
  2. Any other reason that, in the Investigator's opinion, makes the participant unsuitable to participate in this study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
70 participants (estimated)
Patient registry
No

Groups and cohorts

  • HL Participants: BV Salvage Pre-ASCT

    Participants diagnosed with HL who undergone or undergoing pre-ASCT BV salvage and continue with post-ASCT treatment will be observed prospectively over 24-month period after treatment cessation.

    Other: No Intervention

  • HL Participants: BV Consolidation Treatment Post-ASCT

    Participants diagnosed with HL who undergone or undergoing post-ASCT BV consolidation treatment will be observed prospectively over 24-month period after treatment cessation.

    Other: No Intervention

Interventions

  • OtherNo Intervention

    This is a non-interventional study.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) as Assessed by Investigator

    PFS will be assessed by investigator and defined as the time from the first dose of BV post ASCT until the first occurrence of disease progression or relapse, or death for any reason. Disease progression is at least a 50 percent (%) increase in the size of lesions, or the occurrence of new lesions. It will be analyzed using Kaplan-Meier method.

    Time frame: From initiation of BV treatment post-ASCT until disease progression or relapse, or death (up to 36 months)

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from initiation of therapy to death from any cause. It will be analyzed using Kaplan-Meier method.

    Time frame: From initiation of BV treatment until death from any cause (up to 36 months)

07

Study locations

13 of 13 sites recruiting
  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu
    Wroclaw, Dolnoslskie 50-556, Poland
    Recruiting
    • Site Contact · Contactkhn@usk.wroc.pl · 48 71 784 25 76
    • Tomasz Wrobel · Principal investigator
  • Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu
    Poznan, Greater Poland Voivodeship 61-848, Poland
    Recruiting
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy Oddzial w Krakowie
    Krakow, Lesser Poland Voivodeship 31-115, Poland
    Recruiting
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie
    Krakow, Lesser Poland Voivodeship 31-501, Poland
    Recruiting
  • Centrum Onkologii Ziemi Lubelskiej im. sw. Jana z Dukli
    Lublin, Lublin Voivodeship 20-090, Poland
    Recruiting
    • Site Contact · Contactcozl@cozl.eu · 48 81 454 1226
    • Marta Morawska · Principal investigator
  • NU-MED Specjalistyczny Szpital Onkologiczny Tomaszow Mazowiecki
    Tomaszow Mazowiecki, Masovian Voivodeship 97-200, Poland
    Recruiting
  • Uniwersyteckie Centrum Kliniczne WUM
    Warsaw, Masovian Voivodeship 02-097, Poland
    Recruiting
    • Site Contact · Contactkho.csk@uckwum.pl · 48 22 599 28 18
    • Joanna Drozd-Sokolowska · Principal investigator
  • Instytut Hematologii i Transfuzjologii
    Warsaw, Masovian Voivodeship 02-776, Poland
    Recruiting
    • Site Contact · Contacthemsek@ihit.waw.pl · 48 22 34 96 334
    • Agnieszka Kolkowska-Lesniak · Principal investigator
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
    Warsaw, Masovian Voivodeship 02-781, Poland
    Recruiting
  • Uniwersyteckie Centrum Kliniczne, Gdansk
    Gdansk, Pomeranian Voivodeship 80-214, Poland
    Recruiting
    • Site Contact · Contactinfo@uck.gda.pl · 48 58 349 20 00
    • Jan Zaucha · Principal investigator
  • Samodzielny Publiczny Szpital Kliniczny im. Andrzeja Mieleckiego Slskiego Uniwersytetu Medycznego w Katowicach
    Katowice, Slskie 40-027, Poland
    Recruiting
    • Site Contact · Contactklinhem@sum.edu.pl · 48 32 256 28 58
    • Ryszard Wichary · Principal investigator
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej MSWiA z Warminsko - Mazurskim Centrum Onkologii w Olsztynie
    Olsztyn, Warmian-Masurian Voivodeship 10-228, Poland
    Recruiting
  • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii, im. M. Kopernika w Lodzi
    Lodz, Łódź Voivodeship 93-513, Poland
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Jan 2027, 58 months after the start.

Of 66 observational studies under Hodgkin Disease, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 149. This study's planned 58 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2021
First posted
Oct 29, 2021
StartActual
Mar 8, 2022
Primary completionEst.
Jan 13, 2027
CompletionEst.
Jan 13, 2027
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05100056
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Oct 29, 2021
Start date
Mar 8, 2022
Primary completion
Jan 13, 2027 (estimated)
Completion
Jan 13, 2027 (estimated)
Last update
May 27, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion